License – Talk Bio

Glenmark Pharma Signs $1.1 Billion Deal with Hengrui for HER2-Targeted Antibody-Drug Conjugate

1 month ago talkbio0Tagged Cancer Therapeutic Procedure, Glenmark, Hengrui Pharma, HER2-targeting antibody drug conjugate, License, milestone payments, Neoplasms, royalties, Trastuzumab Rezetecan

Glenmark; Hengrui Pharma; Trastuzumab Rezetecan; HER2-targeting antibody drug conjugate; oncology; exclusive license; $1.1 billion deal; cancer therapy; milestone payments; royalties

Fosun Licenses Immunology Asset FXS6837 to Sitala in $670M Deal

2 months ago talkbio0Tagged Autoimmune Diseases, Fosun Pharma, FXS6837, Immunology, License, Sitala

Fosun Pharma; Sitala; FXS6837; immunology; license agreement; autoimmune diseases; biotech; pharmaceuticals; $670 million

Novartis Bets on Covalent Chemistry in $1B Matchpoint Therapeutics Deal

3 months ago talkbio0Tagged Advanced phase, biotechnology partnerships, covalent chemistry, Covalent Interaction, Drug Development, Inflammatory disorder, License, Matchpoint Therapeutics, Novartis, oral inhibitors

Novartis; Matchpoint Therapeutics; covalent chemistry; exclusive option and license agreement; inflammatory diseases; oral inhibitors; Advanced Covalent Exploration platform; drug development; biotechnology partnerships